Omidubicel is under clinical development by Gamida Cell and currently in Phase II for Aplastic Anemia. According to GlobalData, Phase II drugs for Aplastic Anemia have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Omidubicel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Omidubicel overview

Omidubicel (Nicord) is under development for the treatment of hemoglobinopathies including sickle cell disease, beta-thalassemia, aplastic anemia and hematological malignancies like chronic myelocytic leukemia (CML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS) and for the use in hematopoietic stem cell transplantation. The therapeutic candidate is administered as an infusion. It is an allogeneic ex-vivo-expanded umbilical cord blood-derived hematopoietic CD34 positive progenitor cells and allogeneic non-expanded umbilical cord blood-derived hematopoietic mature myeloid and lymphoid cells. The therapeutic candidate is developed based on NAM platform technology. It was also under development for the treatment of Hodgkin lymphoma and non-Hodgkin lymphoma, acute myelocytic leukemia (AML).

Gamida Cell overview

Gamida Cell (Gamida) is a health care company. It offers cell therapy developing cell and immune therapy technologies for treating blood cancers and serious blood disorders. Its pipeline products include Omidubicel an advanced cell therapy being developed as an allogeneic hematopoietic stem cell (bone marrow) transplant solution for treating hematologic malignancies and severe aplastic anemia; GDA-201 an innate natural killer cell immunotherapy used for the treatment of hematologic and solid tumors. Gamida utilizes NAM technology platform to develop its products. Gamida is headquartered in Jerusalem, Israel.

For a complete picture of Omidubicel’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.